Current White Papers
Asset Identification Series - Early Stage Asset Identification (pdf)
The cost of drug development averages >$1.3B from laboratory to FDA approval and is increasing. To decrease barriers and reduce pressure on R&D teams, it is becoming increasingly common to outsource technologies through acquisition of smaller companies and licensing agreements of early stage therapeutics.
Asset Identification Series - Asset Valuation & Risk Assessment (pdf)
After identifying a potential asset, it is critical to accurately value it, both in terms of financial and time costs and potential risk.
Anatomy of a Licensing Agreement (pdf)
Licensing agreements allow small biotech firms or academic institutions to carry a novel therapeutic through clinical trials and commercialization by partnering with an existing, larger pharmaceutical company that can take on the financial risk and burden.
Forecasting Gene Therapy (pdf)
The field of gene therapy is evolving rapidly and presents new challenges for those forecasting both disease cases and annual sales. Gene therapies are expected to be, in many cases, curative and will be launched at unprecedented prices, two nuances which require novel methods to predict both the future epidemiological and market landscapes.
The cost of drug development averages >$1.3B from laboratory to FDA approval and is increasing. To decrease barriers and reduce pressure on R&D teams, it is becoming increasingly common to outsource technologies through acquisition of smaller companies and licensing agreements of early stage therapeutics.
Asset Identification Series - Asset Valuation & Risk Assessment (pdf)
After identifying a potential asset, it is critical to accurately value it, both in terms of financial and time costs and potential risk.
Anatomy of a Licensing Agreement (pdf)
Licensing agreements allow small biotech firms or academic institutions to carry a novel therapeutic through clinical trials and commercialization by partnering with an existing, larger pharmaceutical company that can take on the financial risk and burden.
Forecasting Gene Therapy (pdf)
The field of gene therapy is evolving rapidly and presents new challenges for those forecasting both disease cases and annual sales. Gene therapies are expected to be, in many cases, curative and will be launched at unprecedented prices, two nuances which require novel methods to predict both the future epidemiological and market landscapes.